Baloxavir Marboxil
Single-dose oral treatment and post-exposure prophylaxis of influenza A and B
- CAS No.
- 1985606-14-1
- Indication Class
- Anti-infectives
- Patent Expiry
- Expiring in 3-5 yrs · 2031 (indicative)
- Therapeutic Area
- Anti-infective / Antiviral
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 4 key intermediates available
- Patent Scope
- Compound patent in major markets
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherListing Logic · Why It's Worth Listing
A novel single-oral-dose influenza agent with concentrated seasonal demand; integrated API-to-finished supply is attractive for regional pandemic stockpiling.
Anti-infective / Antiviral · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
4 key intermediates available; scale-up and cost control manageable
Product Description
Baloxavir marboxil is an oral antiviral medication used for the treatment of acute, uncomplicated influenza (flu) in adults and children.
Supply source: Unibest · Baloxavir Marboxil, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.